ASX-LISTED CSL Limited yesterday reported a whopping 29% increase in net profit after tax, which surged to more than $1.7 billion for the year to 30 Jun.
The strong result saw CSL's share price jump more than $12 to $214, with ceo Paul Perreault highlighting the success of CSL's Seqirus vaccines business both in Australia and the USA.
In America Seqirus' Holly Springs influenza vaccine facility quadrupled the number of doses produced this season for the US market, while overall sales of the Fluad adjuvanted influenza vaccine for seniors jumped 142%.
Perrault also noted the performance of CSL's plasma-based therapies, with the global commercial rollout of Idelvion providing Haemophilia B patients with a new standard of care.
"The tightness in supply of our key raw material, plasma, has been a feature across the industry this year," he said, with CSL opening 27 new collection centres in the USA and now operating 206 globally.
Innovation and development is ongoing, with approvals of new indications for CSL products such as Privigen and Hizentra, as well as the recent acquisition of the Calimmune proprietary stem cell gene therapy platform.
The CSL ceo said the company was continuing to anticipate strong demand for its products, with net profit after tax for 2019 anticipated to be up to $1.95 billion, an increase of 10-14%.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Aug 18
